MC1R common variants, CDKN2A and their association with melanoma and breast cancer risk
Corresponding Author
Tadeusz Dȩbniak
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Fax: +48-91-4661533
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Połabska 4, 70-115 Szczecin, PolandSearch for more papers by this authorRodney Scott
Discipline of Medical Genetics, Faculty of Health, University of Newcastle, Newcastle, Australia
Hunter Medical Research Institute, University of Newcastle, Newcastle, Australia
Search for more papers by this authorBartłomiej Masojc
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorPablo Serrano-Fernández
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorTomasz Huzarski
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorTomasz Byrski
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorBogusław Dȩbniak
Regional Hospital, Gorzów Wielkopolski, Poland
Search for more papers by this authorBohdan Górski
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorCezary Cybulski
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorKrzysztof Mȩdrek
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorGrzegorz Kurzawski
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorThierry van de Wetering
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorRomuald Maleszka
Department of Dermatology and Venerology, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorJózef Kładny
III Department of Surgery, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorJan Lubinski
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorCorresponding Author
Tadeusz Dȩbniak
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Fax: +48-91-4661533
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Połabska 4, 70-115 Szczecin, PolandSearch for more papers by this authorRodney Scott
Discipline of Medical Genetics, Faculty of Health, University of Newcastle, Newcastle, Australia
Hunter Medical Research Institute, University of Newcastle, Newcastle, Australia
Search for more papers by this authorBartłomiej Masojc
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorPablo Serrano-Fernández
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorTomasz Huzarski
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorTomasz Byrski
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorBogusław Dȩbniak
Regional Hospital, Gorzów Wielkopolski, Poland
Search for more papers by this authorBohdan Górski
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorCezary Cybulski
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorKrzysztof Mȩdrek
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorGrzegorz Kurzawski
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorThierry van de Wetering
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorRomuald Maleszka
Department of Dermatology and Venerology, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorJózef Kładny
III Department of Surgery, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorJan Lubinski
Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
Search for more papers by this authorAbstract
We sought to examine the association between MC1R variants and the risk of melanoma and breast cancer in Polish population. We also determined the prevalence of compound heterozygous carriers of MC1R and CDKN2A (A148T) variants. We examined 500 unselected melanoma cases, 511 consecutive invasive breast cancer patients, 800 newborns, 421 healthy adults matched for sex and age with the melanoma cases and 511 healthy women matched for sex and age with the breast cancer cases. A statistically significant association of all 4 MC1R variants with the melanoma risk was found. For the R151C variant p value was 0.000008 and odds ratio 2.9; for the V60L variant p value was 0.007 and OR 1.78; for the R160C p was 0.006 and OR 1.76; for the R163Q p was 0.015 and odds ratio 2.1. None of the compound heterozygotes were significantly over-represented among any of the melanoma cases, the highest OR (4.2) observed in patients harbouring the A148T variant in CDKN2A and the R151C variant in MC1R. Positive association was found between carrying any of the MC1R variants and (i) increased occurrence of melanoma among I degree relatives of the carriers; (ii) increased occurrence of melanoma on UV-non-exposed skin areas. We also observed a tendency of increased risk of multiple melanomas among carriers of MC1R variants. The haplotype analysis demonstrates that MC1R variants do not co-occur in cis, compound carriers have both alleles affected. We found no association with the MC1R variants and breast cancer risk. In conclusion, the results of this population-based study show herein that MC1R variants are associated with increased melanoma risk in the Polish population. The risk of disease seems to be increased additively for patients harbouring also the CDKN2A common variant A148T. © 2006 Wiley-Liss, Inc.
References
- 1 Valverde P, Healy E, Jackson I, Rees JL, Thody AJ. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995; 11: 328–30.
- 2 Palmer JS, Duffy DL, Box NF, Aitken JF, O'Gorman LE, Green AC, Hayward NK, Martin NG, Sturm RA. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000; 66: 176–86.
- 3 Box NF, Wyeth JR, O'Gorman LE, Martin NG, Sturm RA. Characterization of melanocyte stimulating hormone receptor variant alleles in twins with red hair. Hum Mol Genet 1997; 6: 1891–7.
- 4 Box NF, Duffy DL, Chen W, Stark M, Martin NG, Sturm RA, Hayward NK. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001; 69: 765–73.
- 5 Chaudru V, Laud K, Avril MF, Miniere A, Chompret A, Bressac-de Paillerets B, Demenais F. Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees. Cancer Epidemiol Biomarkers Prev 2005; 14: 2384–90.
- 6 Begg CB, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 2005; 97: 1507–15.
- 7 Matichard E, Verpillat P, Meziani R, Gerard B, Descamps V, Legroux E, Burnouf M, Bertrand G, Bouscarat F, Archimbaud A, Picard C, Ollivaud L, et al. Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure. J Med Genet 2004; 41: e13.
- 8 Kennedy C, ter Huurne J, Berkhout M, Gruis N, Bastiaens M, Bergman W, Willemze R, Bavinck JN. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001; 117: 294–300.
- 9 Valverde P, Healy E, Sikkink S, Haldane F, Thody AJ, Carothers A, Jackson IJ, Rees JL. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996; 5: 1663–6.
- 10 Landi MT, Kanetsky PA, Tsang S, Gold B, Munroe D, Rebbeck T, Swoyer J, Ter-Minassian M, Hedayati M, Grossman L, Goldstein AM, Calista D, et al. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst 2005; 97: 998–1007.
- 11 Stratigos AJ, Dimisianos G, Nikolaou V, Poulou M, Sypsa V, Stefanaki I, Papadopoulos O, Polydorou D, Plaka M, Christofidou E, Gogas H, Tsoutsos D, et al. Melanocortin receptor-1 gene polymorphisms and the risk of cutaneous melanoma in a low-risk southern European population. J Invest Dermatol, in press.
- 12 Fargnoli MC, Altobelli E, Keller G, Chimenti S, Hofler H, Peris K. Contribution of melanocortin-1 receptor gene variants to sporadic cutaneous melanoma risk in a population in central Italy: a case-control study. Melanoma Res 2006; 16: 175–82.
- 13 Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA, Strange RC. Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes. Br J Cancer 2001; 85: 1504–9.
- 14 Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004; 75: 1131–5.
- 15 Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WH,Jr, Tucker MA. Increased risk of pancreatic cancer in melanoma-prone families with p16INK4 mutations. New Engl J Med 1995; 333: 970–4.
- 16 Debniak T, Scott RJ, Huzarski T, Byrski T, Rozmiarek A, Debniak B, Zaluga E, Maleszka R, Kladny J, Gorski B, Cybulski C, Gronwald J, et al. CDKN2A common variants and their association with melanoma risk: a population-based study. Cancer Res 2005; 65: 835–9.
- 17 Debniak T, Gorski B, Huzarski T, Byrski T, Cybulski C, Mackiewicz A, Gozdecka-Grodecka S, Gronwald J, Kowalska E, Haus O, Grzybowska E, Stawicka M, et al. A common variant of CDKN2A (p16) predisposes to breast cancer. J Med Genet 2005; 42: 763–5.
- 18 Dȩbniak T, Scott RJ, Huzarski T, Byrski T, Masojć B, van de Wetering T, Serrano-Fernandez P, Górski B, Cybulski C, Gronwald J, Dȩbniak B, Maleszka R, et al. XPD common variants and their association with melanoma and breast cancer risk. Breast Cancer Res Treat, in press.
- 19 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
- 20 Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463–7.
- 21 Ott J. Utility programs for analyisis of genetic linkage; Program HWE, 1988. Available at http://www.hgmp.mrc.ac.uk/Registered/Help/linkutil/.
- 22 Ding K, Zhou K, He F, Shen Y. LDA-a java-based linkage disequilibrium analyzer. Bioinformatics 2003; 19: 2147, 2148.
- 23 Van der Velden PA, Sandkuijl LA, Bergman W, Pavel S, van Mourik L, Frants RR, Gruis NA. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 2001; 69: 774–9.
- 24 Gorski B, Narod SA, Lubinski J. A common missense variant in BRCA2 predisposes to early onset breast cancer. Breast Cancer Res 2005; 7: R1023–7.
- 25 The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999; 91: 1310–6.
- 26 Justenhoven C, Hamann U, Pesch B, Harth V, Rabstein S, Baisch C, Vollmert C, Illig T, Ko YD, Bruning T, Brauch H. ERCC2 genotypes and a corresponding haplotype are linked with breast cancer risk in a German population. Cancer Epidemiol Biomarkers Prev 2004; 13: 2059–64.
- 27 Baccarelli A, Calista D, Minghetti P, Marinelli B, Albetti B, Tseng T, Hedayati M, Grossman L, Landi G, Struewing JP, Landi MT. XPD gene polymorphism and host characteristics in the association with cutaneous malignant melanoma risk. Br J Cancer 2004; 90: 497–502.
- 28 Tomescu D, Kavanagh G, Ha T, Campbell H, Melton DW. Nucleotide excision repair gene XPD polymorphisms and genetic predisposition to melanoma. Carcinogenesis 2001; 22: 403–8.
Citing Literature
